buyWeak
EcoR1 Capital, LLC bought $1.9M of ZYME
director, owner at Zymeworks Inc.. 130,309 shares at an average of $14.44, traded Dec 24, 2024, filed Dec 27, 2024.
Conviction score
35Value
$1.9M
130,309 shares
Holdings after
14,822,590
+1% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0000935836-24-000785, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 24, 2024 | POpen-market purchase Common Stockindirect: See Note | +11,958 | $14.12 | $169k | 14,704,239 | Dec 27, 2024 |
| Dec 26, 2024 | POpen-market purchase Common Stockindirect: See Note | +16,692 | $14.38 | $240k | 14,720,931 | Dec 27, 2024 |
| Dec 27, 2024 | POpen-market purchase Common Stockindirect: See Note | +101,659 | $14.49 | $1.5M | 14,822,590 | Dec 27, 2024 |
Related signals
Other insiders at Zymeworks Inc. and this insider’s other filings.
| Score | Side | Company | Insider | Value | Shares | Filed |
|---|---|---|---|---|---|---|
| 25Weak | sell | ZYME Zymeworks Inc. | Schayowitz Adam EVP, Head of R&D | $358k | 13,832 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.